Tiziana Life Sci PLC (NASDAQ:TLSA LON:TILS) Dr Kunwar Shailubhai, CEO & CSO
Jul 22, 2019, 08:25 AM
We are very pleased with the clinical activity and tolerability of Milciclib in these advanced cases of HCC. It is an important milestone to move forward with the further clinical development of Milciclib either as a single agent or in combination with other HCC drugs," said Dr Kunwar Shailubhai, CEO & CSO of Tiziana.